Shenzhen JYMed Technology Co., Ltd.

Peptides have been extensively studied in nanomedicine with great bioactivity and biocompatibility; however, their poor cell-membrane-penetrating properties and nonselectivity greatly limit their clinical applications. In this study, tumor-targeting therapy was achieved by modifying our previously developed efficient peptide vector with the cancer-targeting peptide RGD, enabling it to specifically target tumor cells with a high expression of RGD-binding receptors. B-cell lymphoma-2 antisense oligonucleotides were selected as the target model to validate the effectiveness of the delivery carriers. Results demonstrated that this delivery system can be efficiently and selectively taken up by RGD receptor-positive cells (α_vβ₃ integrin receptor), further inducing effective target gene knockdown. Overall, this system provided a promising strategy for the targeted delivery of nucleic acid drugs.

Liraglutide, an analog of glucagon‐like peptide‐1, is a treatment for the management of type 2 diabetes mellitus and obesity. In this study, we developed and validated a straightforward, sensitive, and reproducible gradient reverse‐phase high‐performance liquid chromatographic method for the separation and quantification of related substances in liraglutide drug substance. A C8 column was employed as the chromatographic column, with a mobile phase comprising phosphate buffer solution and acetonitrile. Under optimized chromatographic conditions, five specific impurities within liraglutide could be efficiently separated simultaneously. The resolution between main peak and each impurity was greater than 1.0, and the tailing factor of the main peak was less than 1.0. This method exhibited high sensitivity and enabled quantitative determination of both liraglutide and each impurity, thereby effectively ensuring the quality control of liraglutide products. The developed method is validated in accordance with the guidelines set by the International Conference on Harmonization regarding specificity, linearity, limit of detection, limit of quantification, accuracy, precision, and robustness.

Objective To prepare nesiritide acetate sustained-release microspheres, investigate the property of in vitro drug release for the sustained-release effect, and reduce the frequency of drug use.Methods Nesiritide acetate sustained-release microspheres were prepared by double-elusion drying in liquid with PLGA as the carrier, Et acetate as the organic solvent, CMC water solution as the dispersion medium and mannitol as the diluents, and freezing drying.The prescription and preparation process were optimized by orthogonal test with particle size, yield and encapsulation as the indexes.The property of in vitro drug release was determinedWe calculated the cumulative drug-releasing percentage of sustained-release microspheres and obtained the drug-releasing curve.Results The prescription and preparation process was screened according to the orthogonal test with a drug loading capacity of 37.3%, an encapsulation efficiency of 91.2% and a zeta potential of (-27.8±1.72) mV.The in vitro releasing profile was in accordance with Higuchi equation.Conclusion The nesiritide acetate sustained-release microspheres for injection have a long time release effect.